Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Recurrence × PEGPH20 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 8 Neoplasm Metastasis 3 Neoplasms 2 Carcinoma, Pancreatic Ductal 2 Adenocarcinoma 2 Thromboembolism 1 Stomach Neoplasms 1 Recurrence 1 Pancreatic Ductal Adenocarcinoma 1 Pancreatic Adenocarcinoma 1 Metastatic Pancreatic Adenocarcinoma 1 Esophageal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 136 Dexamethasone 118 Rituximab 75 fludarabine 65 Lenalidomide 60 Cytarabine 59 Gemcitabine 55 Bortezomib 52 fludarabine phosphate 51 venetoclax 47 pembrolizumab 46 Etoposide 46 Paclitaxel 45 Carboplatin 44 Cisplatin 43 pomalidomide 41 Peripheral Blood Stem Cell Transplantation 39 Radiotherapy 38 Filgrastim 38 Bevacizumab 33 Melphalan 32 Busulfan 32 carfilzomib 30 Calcium Dobesilate 30 Methotrexate 29 Cyclosporine 29 Azacitidine 28 Mycophenolic Acid 26 Temozolomide 25 Nivolumab 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02346370 2019-02-08

PRIMAL

Halozyme Therapeutics

Phase 1 Terminated

16 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡